Wegovy, Water Weight and What the Scales Are Actually Telling You

The first few weeks: you step on the scales and the number moves fast

Picture this: it's two weeks into your first Wegovy pen, you're eating noticeably less, and the scales are already showing a 3 or 4 kg drop. It feels encouraging, but also slightly unreal. That instinct is worth trusting. A large share of early weight change on any significant calorie reduction is fluid rather than fat tissue, and GLP-1 treatment is no different.

Here's the mechanism. Your muscles and liver store carbohydrate as glycogen. For every gram of glycogen, your body holds roughly 3 grams of water alongside it. When food intake falls sharply (as it typically does once semaglutide begins suppressing appetite) glycogen stores are drawn down, and the water bound to them is released and excreted. The result is a real, measurable drop on the scales that has nothing to do with fat loss. It's genuine progress in one sense: your body is responding. But it's not the same process as the sustained fat reduction that follows over the months ahead, as described in the clinical overview of semaglutide.

The STEP 1 trial, published in the New England Journal of Medicine, reported around 15% average body-weight reduction over 68 weeks at the 2.4 mg maintenance dose. That figure reflects sustained loss over more than a year, not the first fortnight. Knowing that early fluid movement is part of the picture helps you read those weekly numbers without over-interpreting a plateau that arrives around week three or four.

Why Wegovy can also cause fluid retention, and when that matters

The picture isn't only one-directional. Some people starting semaglutide notice mild puffiness, particularly around the ankles or hands, in the early weeks. This is less well-publicised than the rapid early loss, but it happens. One likely contributor is the body's insulin-response changes: as blood sugar regulation shifts, the kidneys temporarily adjust how much sodium (and with it, water) they retain.

Reduced movement can play a role too. Nausea is the most commonly reported side effect when starting or increasing the dose, and it can mean sitting or lying down more than usual. Less movement means less of the pumping action that helps fluid return from the legs. The NHS medicines page for semaglutide lists nausea, vomiting and diarrhoea as the most frequent early side effects, worth reading before your first pen arrives.

Mild fluid retention usually resolves on its own as your body adjusts and activity picks back up. Persistent swelling, shortness of breath or swelling in one leg that is noticeably worse than the other are not normal, those warrant a call to your GP or care team, not a wait-and-see approach. More detail on managing side effects sits on the full Wegovy treatment page.

Dehydration: the fluid problem that actually needs acting on

While water weight fluctuation is largely passive (something that happens to you) dehydration is the fluid issue that requires your attention. GLP-1 medicines reduce appetite, and for many people that appetite suppression extends to drinking less as well as eating less. Add in nausea, vomiting or diarrhoea during dose escalation and the risk climbs further. Dehydration can affect kidney function, worsen headaches and fatigue, and make nausea harder to manage, a cycle worth breaking early.

The practical guidance from NHS England's weight management injections resource emphasises that patients should maintain good fluid intake throughout treatment. Set a routine if you need one: a glass of water before each meal, another mid-morning and mid-afternoon. Plain water is the priority, and our guidance on Wegovy and water explains exactly why staying well hydrated matters and how to build it into your daily routine. If you find yourself going hours without wanting to drink, that is something to mention to your prescriber at the next review.

There's a broader point here about what the scales record day to day. Daily weigh-ins capture fluid state as much as anything else, what you drank yesterday, where you are in your menstrual cycle, whether you ate something higher in salt. A weekly weigh-in at the same time of day gives a cleaner signal, and a four-week trend tells you more than any single morning's number. The relationship between Wegovy and weight change over time is a question our prescribers hear often; it's worth reading before your first review.

How to think about water weight when evaluating your progress

Separating fluid from fat matters most at two points: the start of treatment, when loss feels dramatic, and any plateau that follows, when progress feels absent. Both can be misleading without context. Fat loss measured in a clinical setting typically runs at a rate of 0.5–1% of body weight per week on a well-managed GLP-1 programme, slower than glycogen-driven water loss, but sustained over many months rather than days.

Body composition measures, waist circumference tracking and how clothes fit alongside the scales all give a more rounded picture than a single number. If you're using a smart scale that estimates body fat percentage, treat those readings as rough trend indicators rather than precise figures, the methods these devices use are sensitive to hydration state, so a well-hydrated weigh-in and a slightly dehydrated one can produce readings several percentage points apart.

Questions about fluid intake guidance during treatment come up regularly; there's a dedicated page that goes deeper. For a sense of what treatment typically costs as a private patient, the Wegovy cost page covers what private pricing includes and what to watch for. If you're ready to find out whether semaglutide is clinically suitable for you, a prescriber from our team (a real clinician, not a decision algorithm) reviews every consultation the same day it's submitted. Speak to our prescribers through the free consultation.